AQR Capital Management LLC Has $17.07 Million Position in Pfizer Inc. (NYSE:PFE)

AQR Capital Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.6% in the second quarter, according to its most recent filing with the SEC. The firm owned 612,429 shares of the biopharmaceutical company’s stock after acquiring an additional 9,435 shares during the period. AQR Capital Management LLC’s holdings in Pfizer were worth $17,068,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PFE. Wellington Management Group LLP lifted its holdings in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after acquiring an additional 11,099,024 shares during the period. Marshall Wace LLP grew its holdings in shares of Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares during the last quarter. Swedbank AB bought a new position in Pfizer during the 1st quarter valued at about $172,902,000. Pzena Investment Management LLC boosted its position in Pfizer by 181.6% in the first quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock valued at $212,855,000 after buying an additional 4,947,000 shares in the last quarter. Finally, FIL Ltd boosted its position in Pfizer by 97.1% in the fourth quarter. FIL Ltd now owns 7,582,518 shares of the biopharmaceutical company’s stock valued at $218,301,000 after buying an additional 3,734,595 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, September 16th. Wells Fargo & Company boosted their price objective on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Finally, Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Nine analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Down 0.9 %

Shares of NYSE PFE opened at $28.67 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $162.46 billion, a PE ratio of -477.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.68. The firm’s 50-day moving average is $29.28 and its 200-day moving average is $28.31. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $34.11.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. Equities analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.